FDA Approves Glucagon Agent as Diagnostic Aid for Abdominal X-Rays
Indicated for IV use, Gvoke VialDx reportedly inhibits movement of the gastrointestinal tract temporarily to facilitate abdominal X-rays.
The Food and Drug Administration (FDA) has approved Gvoke VialDx, a gastrointestinal motility inhibitor for abdominal X-rays in adult patients.
A concentrated liquid glucagon, Gvoke VialDx reportedly enables temporary inhibition of the gastrointestinal tract during imaging, according to Xeris Biopharma, the developer of Gvoke VialDx.
“Gvoke VialDx has the potential to modernize the handling and administration of glucagon for diagnostic procedures,” said Kevin McCulloch, the president and chief operating officer of Xeris Biopharma.
Pointing out that Gvoke VialDx may cause hyperglycemia in patients with diabetes mellitus, Xeris Biopharma emphasized monitoring of these patients during the use of Gvoke VialDx. The company also cautioned that monitoring is necessary in patients with cardiac disease as Gvoke VialDx may lead to increased myocardial oxygen demand, blood pressure and pulse rate, which can be life-threatening in this patient population.
Xeris Biopharma said Gvoke VialDx is contraindicated in patients with pheochromocytoma, insulinoma, glucagonoma and prior sensitivity reaction to glucagon.
Noting that the gastrointestinal motility inhibitor is expected to be available in the third quarter of 2025, Xeris Biopharma noted that Gvoke VialDx ca be purchased as one or 10-count packages of 1 mg per 0.2 mL single-dose vials.
Study: AI Bolsters Sensitivity for Pneumothorax on CXR and Significantly Reduces Reporting Time
October 30th 2024For clinically actionable pneumothorax, an artificial intelligence algorithm demonstrated a 93 percent AUC and a 96 percent specificity rate in a study involving chest X-rays from over 27,000 adults.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
